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NitroglycerinAbstract Background: The study was designed to assess the ability of dexmedetomidine in differ-
ent regimens to produce controlled hypotensive anesthesia during functional endoscopic sinus sur-
gery in adults and the need to add an additional hypotensive agent in the form of nitroglycerin to
achieve the target MAP.
Methods: In this blinded randomized controlled trail, 45 Patients, aged from 18 to 50 years, ASA
physical status I and II, underwent endoscopic sinus surgery were enrolled in the study. Before
induction of GA, all patients received bolus dexmedetomidine 1 l/kg iv more than 10 min. After
induction, Patients were randomly allocated into three groups, group Dex-0.4, in which patients
received dexmedetomidine infusion as 0.4 lg/kg/h, group Dex-0.8, in which patients received dex-
medetomidine infusion as 0.8 lg/kg/h and group Dex-P, in which patients received saline infusion.
The target MAP was 55–65 mmHg, if not achieved by the infused study drug, nitroglycerin infusion
was added in a titrating manner started with 0.1 lg/kg/min and increased gradually till the target
MAP is reached. The surgical ﬁeld quality was assessed by using Fromme et al. bleeding score.
Results: The intraoperative MAP in group Dex-P and group Dex-0.8 was maintained within target
range at all time intervals. In group Dex-0.4, the MAP showed ﬂuctuation to fall below and
increased above the target range at different time intervals. Unlike the other two groups, no
nitroglycerin infusion was needed in group Dex-0.8. Fromme et al. bleeding score showed the lowest
values in Dex-0.8 group and the highest values in group Dex-0.4. The differences between the three
groups were statistically signiﬁcant with (P< 0.05).
340 N.I. Abel Rahman et al.Conclusion: Dexmedetomidine as bolus 1 lg/kg iv followed by iv infusion of 0.8 lg/kg/h or dex-
medetomidine as pre-induction bolus 1 lg/kg iv followed by nitroglycerine iv infusion signiﬁcantly
decreased the mean arterial blood pressure to target values and provide satisfactory ﬁeld quality.
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Functional endoscopic sinus surgery (FESS) is a minimally
invasive procedure and is commonly performed under con-
trolled hypotensive anesthesia [1].
Several pharmaceuticals have been used successfully to pro-
duce controlled hypotension during general anesthesia, for
example inhalational anesthetics, direct vasodilators (sodium
nitroprusside and nitroglycerin), beta adrenergic antagonists
(propranolol and esmolol), alpha adrenergic agonists (cloni-
dine and dexmedetomidine), calcium channel blockers, prosta-
glandin E1 (alprostadil) and adenosine [2] and l-receptors
agonists (remifentanil) [3,4].
Dexmedetomidine is a highly selective a2 adreno-receptor
agonist with higher afﬁnity to a2 adreno-receptor than cloni-
dine, and this makes dexmedetomidine primarily sedative
and anxiolytic [5]. The elimination half-life of dexmedetomi-
dine (t1/2b) is 2 h and the redistribution half-life (T1/2a) is
6 min, and this short half-life makes it an ideal drug for intra-
venous titration [6,7].
Several studies proved that intraoperative infusion of
dexmedetomidine reduces the perioperative analgesic require-
ments [8,9], and others studies concluded that dexmedetomi-
dine helps in reducing intraoperative blood pressure and
provide satisfactory surgical ﬁeld conditions [10–12].
The objectives of this prospective randomized controlled
trial were to assess the efﬁcacy of dexmedetomidine in different
regimens to produce controlled hypotensive anesthesia during
functional endoscopic sinus surgery in adults and the need to
add an additional hypotensive agent in the form of nitroglyc-
erin to achieve the target MAP. The primary outcome is the
intraoperative MAP and the amount needed from an addi-
tional hypotensive agent nitroglycerin to achieve the targeted
MAP. The secondary outcomes include intraoperative heart
rate (HR), consumption of other vasoactive drugs (ephedrine,
atropine), intra-operative surgical ﬁeld quality, duration of
recovery, postoperative sedation score and postoperative com-
plications as hemodynamic instability, vomiting, desaturation
or bleeding from surgical ﬁeld.2. Methodology
This study has been conducted in the of the Department of
Anesthesia, ENT operating theater, Cairo University Hospi-
tals through the period from June 2012 to June 2013 after
being approved by the Departmental Research and Ethical
Committee, and after obtaining informed consents from all
patients. 45 Patients, aged from 18 to 50 years, ASA physical
status I and II, underwent functional endoscopic sinus surgery
were enrolled in the study. Patients with cardiovascular disease
(hypertension, congestive heart failure, and coronary artery
disease), cerebrovascular insufﬁciency, coagulation defects,history of renal or hepatic insufﬁciency, and hypersensitivity
to the study drugs were excluded from the study.
On arrival to operating room, no sedation was given, iv
line was cited and lactated ringer solution was infused 4–
6 ml/kg/h. All patients were monitored with non-invasive
blood pressure (BP), electrocardiograph ECG, pulse oximeter
(SpO2) before induction of general anesthesia (GA), capnog-
raphy for end-tidal CO2 (ETCO2), radial artery cannula for
intra-arterial blood pressure monitoring, and peripheral nerve
stimulator (PNS) applied on the ulnar nerve for neuromuscu-
lar blockade after induction of GA. All patients received 1l/
kg iv dexmedetomidine bolus dose more than 10 min before
induction of GA, then anesthesia was induced with propofol
2 mg/kg iv, fentanyl 1 lg/kg iv and atracurium besylate
0.5 mg/kg iv, when TOF count showed disappearance of T1
(0/4), endotracheal intubation with appropriate size oral
endotracheal tube was accomplished and lungs were mechan-
ically ventilated to maintain the ETCO2 30–35 mmHg. Anes-
thesia was maintained with inspired isoﬂurane 1.5 vol% and
atracurium besylate top up doses 0.1 mg/kg/20–30 min was
given guided with TOF count aiming to keep it as 1/4. Airway
was secured by oro-pharyngeal packing and patients were
positioned supine with head up 30. Dexamethasone 0.2 mg/
kg and metoclopramide 10 mg slowly iv were given as emesis
prophylaxis.
Patients then were randomly allocated into three groups,
group Dex-0.4, in which the patients received dexmedetomi-
dine 0.4 lg/kg/h as continuous iv infusion at rate of 0.2 ml/
kg/h from a prepared dexmedetomidine diluted in saline to a
concentration of 2 lg/ml, group Dex-0.8 in which the patients
received dexmedetomidine 0.8 lg/kg/h as continuous iv infu-
sion at rate of 0.2 ml/kg/h from a prepared dexmedetomidine
diluted in saline to a concentration of 4 lg/ml and group
Dex-P (placebo) in which the patients received continuous iv
infusion of 0.2 ml/kg/h of normal saline. The continuous iv
infusion was maintained all through the procedure and termi-
nated 10 min before termination of surgery and discontinua-
tion of inhaled anesthetics. The syringes of the continuous
infusion were prepared by an anesthesiologist who was not
involved in data recording and infused through injector pumps
with unidentiﬁed reservoirs to assure that the observing anes-
thesiologist remained blinded to the infused drug. The target
MAP was 55–65 mmHg, if not achieved by the infused study
drug, nitroglycerin infusion was added in a titrating manner
started with 0.1 lg/kg/min and increased gradually till the tar-
get MAP is reached. If the MAP dropped below 55 mmHg,
nitroglycerin infusion was decreased gradually till stopped
and if the MAP is still below 55 mmHg, ephedrine 6 mg iv
was given and could be repeated after 3 min. Atropine
0.01 mg/kg was given if HR decreased to 50 beat/min.
All patients were operated upon by the same surgeon.
Bleeding in the surgical ﬁeld and the quality of the visibility
were assessed subjectively by the surgeon who was blinded to
Efﬁcacy of different dexmedetomidine regimens 341the infused drug using 6 points scale by Fromm et al. scale [13]
adapted by Boezaart et al. [15]: 0= no bleeding, 1= slight
bleeding so blood evacuation not necessary, 2: slight bleeding
so sometimes blood has to be evacuated, 3 = low bleeding so
blood has to be often evacuated and operative ﬁeld is visible
for some seconds after evacuation, 4= average bleeding so
blood has to be often evacuated, and operative ﬁeld is visible
only right after evacuation and 5= high bleeding so constant
blood evacuation is needed, sometimes bleeding exceeds evac-
uation and surgery is hardly possible. The 1st assessment was
30 min after the beginning of surgery and then every 30 min till
the end of surgery.
All through the intraoperative period, mean arterial blood
pressure (MAP), heart rate (HR), were recorded before start-
ing the bolus infusion of dexmedetomidine (baseline), one
minute after termination of the bolus dexmedetomidine, one
minute after induction of GA, one minute after endotracheal
intubation and then every 10 min throughout the surgery till
patient recovery and one minute before transfer to the post-
anesthesia care unit (PACU). The total amount of nitroglyc-
erine consumed throughout the procedure was recorded for
each patient as mg/patient. With termination of surgery, iso-
ﬂurane was discontinued, the oropharyngeal pack was
removed and the oropharynx was suctioned under direct
vision using the rigid laryngoscope. The residual atracurium
was reversed with neostigmine 0.05 l/kg iv and atropine
0.02 mg/kg iv when the TOF count is 2/4, trachea was extu-
bated once the patients showed eye opening and purposeful
movement and then patients were transferred to PACU where
BP, SpO2 and ECG were monitored. O2 supplementation was
provided via face mask. Sedation was assessed using Ramsay
sedation score (Appendix-1) on arrival to PACU, and then
every 30 min for 2 h. Complications such as desaturation
due to bronchospasm, laryngospasm, bleeding from surgical
site or vomiting were recorded and managed. Recovery char-
acteristics were measured using Modiﬁed Aldrete’s Score
(MAS) on arrival to the PACU and every 30 min. Patients
were discharged from the PACU after achieving a modiﬁed
Aldrete’s score ofP9. The duration of surgery (the time from
start of surgical intervention till its end), the extubation time
(the time from discontinuation of isoﬂurane till removal of
the endotracheal tube), the duration of anesthesia (time span
from induction of general anesthesia till the extubation) and
time for interaction (the time from discontinuation of isoﬂu-
rane till verbal contact or response to commands) were
recorded.Table 1 Patients characteristics, duration of surgery, duration of
studied groups.
Dex-P (n-15)
Age (years) 39 ± 7
Gender (male/female) (9/6)
Weight (kg) 70 ± 9
ASA (I/II) (11/4)
Duration of surgery (min) 118 ± 21
Duration of anesthesia (min) 135 ± 19
Extubation time (min) 15 ± 4
Time of interaction (min) 32 ± 8
Data expressed as mean ± (SD). *means P value <0.05.3. Statistical analysis
We assumed a clinically signiﬁcant difference of 50% reduc-
tion in the requirements of additional hypotensive agent nitro-
glycerine to achieve the target MAP with a power of 80% and
(a= 0.05, one-tailed), and the sample size calculated was 36
patients (12/group) which will be increased to 45 patients
(15/group) for possible dropouts. Microsoft Excel 2010 and
Statistical Package of Social Science software program, version
21 (SPSS) were used for all statistical comparisons (Chicago,
IL, USA). Continuous quantitative normally distributed data
expressed as means and standard deviations (SD). Qualitative
nominal data e.g. incidence of complications expressed as per-
centage. Fisher’s exact test was used as appropriate to compare
qualitative data between the study groups. All other group
comparisons were made using analysis of variant (ANOVA)
test and Kruskal–Wallis ANOVA was used to compare Ram-
say sedation score and Fromme et al. ﬁeld rating scale for
bleeding between the three groups. P values of less than 0.05
were considered statistically signiﬁcant.
4. Results
Forty-ﬁve adult patients, met our inclusion criteria, were
enrolled in the study and randomly allocated into 3 groups,
Dex-P (placebo), Dex-0.4 and Dex-0.8. All patients showed
no signiﬁcant differences regarding age, gender, weight, ASA
classiﬁcation, duration of surgery, duration of anesthesia and
recovery characteristics including extubation time and time
of interaction (Table 1).
The Fromme et al. bleeding score showed the lowest values
in Dex-0.8 group and the highest values in group Dex-0.4. The
differences between the three groups were statistically signiﬁ-
cant with (P< 0.05) at all assessment time points except at
time 60 min, and there was no statistically signiﬁcant differ-
ence between group Dex-P and Dex-0.4 (Table 2).
Among the three groups, the MAP showed no signiﬁcant dif-
ferences between the baseline values and values measured one
minute after bolus dose, after induction ofGAand after endotra-
cheal intubation. The intraoperative MAP values in both group
Dex-PandgroupDex-0.8werekept almost constantwithin target
range of our study all through the time interval, while the intraop-
erativeMAPwithin the groupDex-0.4 showed ﬂuctuation to fall
below the target range at some time intervals (T20, 40, 60, 80) and
above the target range at other time intervals (T50,90) (Fig. 1).anesthesia, extubation time and time of interaction in the three
Dex-0.4 (n-15) Dex-0.8 (n-15)
33 ± 9 42 ± 3
(7/8) (5/10)
68 ± 6 56 ± 11
(13/2) (10/5)
129 ± 18 112 ± 23
141 ± 20 148 ± 17
18 ± 5 21 ± 3
35 ± 8 40 ± 5
Table 2 Surgical ﬁeld quality (Fromme et al. rating scale).
Time of assessment Group Dex-P n= 15 Group Dex-0.4 n= 15 Group Dex-0.8 n= 15
30 min 2.4 ± 0.4* 3.5 ± 0.4* 1.4 ± 0.3*
60 min 2.2 ± 0.3 2.7 ± 0.5 1.2 ± 0.2*
90 min 2.1 ± 0.4* 3.8 ± 0.5* 1.3 ± 0.2*
End of surgery 1.8 ± 0.3 2.1 ± 0.2 0.9 ± 0.2
Data expressed as mean ± SD.
* Means P value < 0.05 among the three groups.
Figure 1 Intraoperative MAP in the 3 groups.
342 N.I. Abel Rahman et al.The baseline HR showed no signiﬁcant difference between
the three groups. One minute after the bolus dose of dexmede-
tomidine, the HR signiﬁcantly decreased, about 25% from the
base line values in the three groups (P< 0.05). HR rate did
not signiﬁcantly change after induction of GA in the three
groups. One minute after tracheal intubation, HR increased in
the three groups but this increase was not signiﬁcant and did
not reach the baseline values. In groupDex-0.8, the HRwas sig-
niﬁcantly lower than that in Dex-0.4 and Dex-P from T20 till
T120 (P< 0.05). HR showed no signiﬁcant difference between
group Dex-0.4 and group Dex-P except at T30,80,130 the HR
was signiﬁcantly higher in group Dex-0.4 (P< 0.05) (Fig. 2).
The number of patients experienced hypotension with
MAP< 55 mmHg and the number of ephedrine doses (one
dose = 6 mg iv) required were signiﬁcantly higher in group
Dex-0.4 when compared to either Dex-P or Dex-0.8. The num-
ber of patients experienced bradycardia with HR< 50 beat/
min and the number of atropine doses were comparable
between the 3 groups (Table 3).
The target MAP was reached in all patients in group Dex-
0.8 without need of using nitroglycerine infusion, unlike
patients in group Dex-0.4 and Dex-p in which all patients
needed nitroglycerine infusion to reach the target MAP. The
requirements of nitroglycerine in group Dex-P were
(10.8 ± 3.2 mg/patient) which was signiﬁcantly higher than
group Dex-0.4 (4.7 + 1.3 mg/patient) (P< 0.05) (Table 3).
Ramsay sedation scores measured in the PACU were signif-
icantly higher in both group Dex-0.8 and Dex 0.4 whencompared to Dex-P at all time intervals. Ramsay score was
higher in group Dex-0.8 when compared with group Dex-0.4
at all-time intervals (P< 0.05) (Fig. 3).
No signiﬁcant difference between the three groups regard-
ing the amount of atracurium besylate consumption, Modiﬁed
Aldrete Score and adverse events as vomiting, laryngeal spasm
or bronchospasm.5. Discussion
In our study, applied on functional endoscopic sinus surgery
in adult, dexmedetomidine as bolus dose 1 lg/kg iv followed
by iv infusion of 0.8 lg/kg/h signiﬁcantly decreased the
MAP pressure to the target level without the need of an
additional hypotensive agent nitroglycerin iv infusion and
it provided the best surgical ﬁeld quality by Fromme
et al. rating score. And also dexmedetomidine as only bolus
1 lg/kg iv followed by nitroglycerine infusion decreased the
MAP to the target level without signiﬁcant increase in the
HR and the surgical ﬁeld conditions were satisfactory for
surgeons. But dexmedetomidine as bolus dose 1 lg/kg iv fol-
lowed by iv infusion of 0.4 lg/kg/h was not sufﬁcient to
lower the MAP to the target level and the use of an addi-
tional hypotensive agent nitroglycerin iv infusion was associ-
ated with ﬂuctuation of the MAP above and below the
target values and the surgical ﬁeld conditions were not sat-
isfactory for surgeons.
Figure 3 Ramsay sedation score: *P< 0.05 among the three groups.
† †
†
Figure 2 Intraoperative HR in the three groups: *P< 0.05 in dex-0.8 vs dex0.4 & dex-p, P< 0.05 in dex-p vs dex-0.4.
Table 3 Nitroglycerine, ephedrine and atropine requirement in the three groups.
Dex-p Dex-0.4 Dex-0.8
Total amount of nitroglycerin used/patient (mg) 10.8 ± 3.2* 4.7 ± 1.3* 0*
Ephedrine:
Number & % of patients
Number of doses/group
3 (20%) 9 (60%) 2 (13.3%)
5 21 2
Atropine:
Number and % of patients
Number of doses/group
0 2 (13.3%) 2 (13.3%)
0 2 (13.3%) 2 (13.3%)
Data expressed as (mean ± SD).
* P-value < 0.05 among the 3 groups.
 P-value < 0.05 (Dex 0.4 versus Dex-p).
 P-value < 0.05 (Dex-0.4 versus Dex-0.8).
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344 N.I. Abel Rahman et al.In our study, we chose a target MAP 55–65 mmHg to pro-
vide the best surgical conditions without the risk of tissue
hypo-perfusion depending on a study conducted by Yoshika-
wa et al. [14] concluded that hypotensive anesthesia induced
by using sodium nitroprusside or nitroglycerine in mandibular
osteotomy to achieve MAP 60–70 mmHg is safe and associ-
ated with no signiﬁcant increase in pyruvate, lactate or glucose
levels, and another study conducted by Boezaart et al. [1] dem-
onstrated that the best surgical conditions for FESS obtained
when the MAP ranged between 50 and 54 mmHg. Also, it is
reported that the best operative ﬁeld quality in FESS surgeries
by using Fromme et al. rating scale is 2–3 points [1,15]
Unfortunately, no sufﬁcient clinical trials studied the effec-
tiveness of combining a2-agonist (either clonidine or dexmede-
tomidine) infusion and direct vasodilator nitroglycerine
infusing in producing controlled hypotensive anesthesia. In a
study conducted by Sahin et al., comparing dexmedetomidine
and alfentanil in producing hypotensive anesthesia during mid-
dle ear surgery, they had to use nitroglycerine iv infusion
started from rate of 0.5 lg/kg/min in 3 out of 20 patients in dex-
medetomidine group to achieve the target MAP 50–65 mmHg,
however, they did not comment on the effect of such combina-
tion [24]. The synergistic effect of combining infusion of dex-
medetomidine and nitroglycerin that found in our study
group Dex-0.4 may be explained by the different mechanisms
of action of both agents, the effect of premedication with a2-
agonist on baroreﬂex response in anesthetized patients and
the patient positioning required during FESS surgery.
Dexmedetomidine stimulates a2-receptors located in pre-
synaptic nerve terminal enhances the negative feedback loop
that inhibits the release of noradrenaline from the nerve ter-
minal [16], while stimulation of the a2-receptor located in
locus ceruleus of brainstem is responsible for the sedative
and hypnotic effect of dexmedetomidine and its ability to
reduce the central sympathetic output [16,17] both cause
vasodilatation and decrease in blood pressure. It is should
be noted that dexmedetomidine stimulates the postsynaptic
a2-receptors in vascular smooth muscle and this produces
vasoconstriction [16] which is opposed by endothelial nitric
oxide synthesis [18].
Nitroglycerin has a non-speciﬁc, direct vasodilator effect on
the venous capacitance vessels and incidentally on the arteries;
it has a short half-life, it increases venous blood volume and
reduces venous return, so cardiac output is proportionally
reduced [2] Nitroglycerin mediates its action via its metabolite
nitric oxide which activates guanylyl cyclase lead to increase
cGMP, this will reduce the intracellular calcium and relax
the vascular smooth muscle [16].
The baroreﬂex response is one of the body’s homeostatic
mechanisms for maintaining the blood pressure; it is mediated
through the baroreceptors located in the aortic arch and carotid
sinuses. The baroreﬂex response to increased blood pressure is
mainly vagal (decreases the heart rate and blood pressure) while
the baroreﬂex response to decreased blood pressure is mainly
sympathetic (increases the heart rate and blood pressure) [19].
In a study conducted by Watanabe et al. [20], they demon-
strated that in patients premedicated with a2-agonist clonidine
and underwent general anesthesia, the baroreﬂex response to
increased blood pressure is unchanged but become attenuated
in response to decreased blood pressure.
The patient’s position during FESS surgeries may play a
role in explain the synergistic action of nitroglycerine and dex-medetomidine. Nitroglycerine especially in small dose causes
vasodilatation more on the capacitance venous vessels rather
than that on the arteriolar vessels, and with the patient’s
supine position with head up 30 commonly used in FESS sur-
geries, polling of the blood into the capacitance vessels helps in
developing some degree of postural hypotension [21].
Referring to previous studies used dexmedetomidine to
induce hypotensive anesthesia, In a placebo controlled clinical
trial conducted by Ayoglu et al. [11], to assess to what extent
the dexmedetomidine at infusion rate of 0.7 lg/kg/h is effective
in reducing the bleeding from the surgical ﬁeld during septo-
plasty and tympanoplasty. Despite authors could not achieve
their target MAP (30% reduction from the preoperative value)
at this infusion rate, but dexmedetomidine succeeded to pro-
vide a good surgical ﬁeld.
Another clinical trial conducted by Aboushanab et al. [12],
comparing the hypotensive effect of dexmedetomidine with
that of magnesium sulfate during middle ear surgeries, they
demonstrated that dexmedetomidine infusion at rate of 0.4–
0.8 lg/kg/h succeeded to reduce the MAP to their target 60–
70 mmHg, despite this MAP is higher than that used in our
study but the authors demonstrated the ability of dexmede-
tomidine to provide very good surgical ﬁeld.
Another placebo controlled trial conducted by Nasreen
et al. [22], using low dose dexmedetomidine (0.4 lg/kg/h) in
addition to titrated halothane vol% in order to reduce MAP
30% from the preoperative values during middle ear surgeries,
they observed signiﬁcant reduction in halothane requirement
in dexmedetomidine group with better surgical ﬁeld compared
to placebo group.
Another observation in our study is the ability of the pre-
induction bolus dose 1 lg/kg of dexmedetomidine to attenuate
the hemodynamic response to direct laryngoscopy and endo-
tracheal intubation as no signiﬁcant increase in HR or MAP
in the 3 groups 1 min after inserting the endotracheal tube,
the same observation was found in a study conducted by
Bajwa et al. [23] whom reported the ability of dexmedetomi-
dine 1 lg/kg iv infusion more than 20 min given as premedica-
tion to attenuate the pressor response to endotracheal
intubation, surgery and extubation.
In our study, there was no signiﬁcant difference in the
extubation time or time of interaction between the three
groups, a ﬁnding that can be explained by nature of dex-
medetomidine as a sedative not hypnotic agent so patients
receiving it will be sedated but easily arousable. Same obser-
vation found by Nasreen et al. [22] who reported signiﬁcant
reduction in the awakening time in patients receiving
dexmedetomidine when compared to placebo group. But in
disagreement with our ﬁnding, Aboushanab et al. [12]
reported longer recovery time in patients receiving dexmede-
tomidine when compared to those received magnesium sulfate
as hypotensive techniques during middle ear surgery. Also
Richa et al [4] reported prolonged extubation time in patients
receiving dexmedetomidine when compared to those received
remifentanil for controlled hypotensive anesthesia during
tympanoplasty.
Our study limitations include the following: ﬁrst inability to
assess the depth of anesthesia and the effect of dexmedetomi-
dine on isoﬂurane requirements due to unavailability of BIS
monitoring. Second we did not use a score for assessing the
postoperative pain, however the FESS is usually followed
headache sensation rather than pain and it was managed
Efﬁcacy of different dexmedetomidine regimens 345successfully by iv paracetamol preparation on patients
complained.
6. Conclusion
From our clinical trial applied on functional endoscopic sinus
surgery in adult ASA I,II we concluded that, dexmedetomidine
regimen as pre-induction bolus dose 1 lg/kg iv followed by
post-induction continuo iv infusion 0.8 lg/kg/h signiﬁcantly
decreased the mean arterial blood pressure to the target level
without the need of an additional hypotensive agent nitroglyc-
erin, and it provides the excellent surgical ﬁeld quality when
compared to other regimens.
Dexmedetomidine used as only pre-induction bolus dose
1 lg/kg iv followed by post-induction nitroglycerine iv infu-
sion decreased the mean arterial blood pressure to the target
level and avoid the reﬂex tachycardia and provide satisfactory
surgical ﬁeld quality.
Conﬂict of interest
No conﬂict of interest in this study.Appendix A. Ramsay sedation score
Score Observation
1 Anxious, agitated or restless
2 Cooperative, oriented and tranquil
3 Responsive to commands
4 Asleep, but with brisk response to light glabellar tap or loud
auditory stimulus
5 Asleep, sluggish response to glabellar tap or auditory
Stimulus
6 Asleep, no responseReferences
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